



JCO2 Rec'd PCT/PTO 15 SEP 2005 PCT

PATENT
ATTORNEY DOCKET NO. 056222-5080-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Andrew CHANTRY *et al.***

Application No.: 10/542,405

International Filing Date: **January 30, 2004**

Filed: **July 15, 2005**

For: **Improvements in or Relating to Control of
Cellular Responsiveness to Hormones**

Group Art Unit: *Unassigned*

Examiner: *Unassigned*

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Dear Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

The documents included in this Information Disclosure Statement (IDS) were cited in an International Search Report dated July 7, 2004, a copy of which is attached for the Examiner's convenience.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that any better art exists and does not constitute an admission that the listed documents are material or constitute "Prior Art." If it should be determined that the listed documents do constitute "Prior Art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.


Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.

§1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP



Erich E. Veitenheimer, III, Ph.D.

Registration No. 40,420

Dated: September 15, 2005
CUSTOMER NO. **009629**
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel: 202.739.3000
Fax: 202.739.3100

1-WA/2446319.1